Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 84

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 84
---
 payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

<div align='center'>64</div>

The Agreement may be terminated by The Company:

| ○ | If Zander has not sold                                                                                                              
 any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve 
 (12) month period after Zander’s first commercial sale of a Licensed Product.                                                       |
| ○ | The Agreement may be terminated                                                                                                     
 by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been   
 granted by the United States patent and Trademark Office to The Company with regard to that License IP.                             |
| ○ | The Agreement may be terminated                                                                                                     
 by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office   
 to The Company with regard to that License IP is terminated.                                                                        |

The Agreement may be terminated by either party in the event of a material breach by the other party.

The CEO of the Company is also the CEO and chairman of Zander.

| ● | Sublease of Facility |

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. On April 26, 2024 the Company and BST agreed to amend that sublease agreement as follows:

The Company agreed that in addition to the base rent of $5,000 per month to be paid by the Company to BST the Company shall also reimburse BST for any and all shared expenses as such term is defined within the original lease agreement by and between BST and CIF LaMesa LLP beginning January 1, 2024.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

| ● | Notes Payable to Related Parties |

The Company had the following notes payable to related party transactions

| ○ | Notes Payable to David                                                                                                      
 Koos, CEO of the Company                                                                                                    |
|   | $73,303 lent to the Company